Crystalline forms of an NK-1 antagonist
The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.
1. A non-solvated crystalline micronized free-base form of the compound 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propenamide having an X-ray powder diffraction pattern comprising the following peak, in terms of 2θ: 11.5°±0.2°.
2. The crystalline form of claim 1 , having an X-ray powder diffraction pattern further comprising the following peak, in terms of 2θ: 13.1°±0.2°.
3. A pharmaceutical composition comprising a non-solvated crystalline micronized free-base form of the compound 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyri din-3-yl)propanamide, having an X-ray powder diffraction pattern comprising the following peak, in terms of 2θ: 11.5°±0.2° and one or more pharmaceutically acceptable excipients.
4. The pharmaceutical composition of claim 3 , wherein the crystalline form further has an X-ray powder diffraction pattern comprising the following peak, in terms of 2θ: 13.1°±0.2°.
5. The compound of claim 1 wherein said compound comprises less than 0.5% impurities.
6. The pharmaceutical composition of claim 3 , wherein the compound is in the form of particles wherein at least 90% of the particles are greater than 0.01 microns and less than 500 microns.
7. The pharmaceutical composition of claim 3 , wherein the compound is in the form of particles wherein at least 90% of the particles are greater than 0.1 microns and less than 100 microns.
8. The pharmaceutical composition of claim 3 wherein said compound comprises less than 0.5% impurities.
9. A crystalline micronized free-base form of the compound 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propenamide comprising one of the following peak, in terms of 2θ: 11.5°±0.2°, wherein the compound is in the form of particles wherein at least 90% of the particles are greater than 0.01 microns and less than 500 microns.
10. The crystalline form of claim 9 , having an X-ray powder diffraction pattern further comprising a peak, in terms of 20 at 4.5°±0.2°.
11. The crystalline form of claim 9 , having an X-ray powder diffraction pattern further comprising the following peak, in terms of 2θ: 13.1°±0.2°.
12. The crystalline form of claim 9 , wherein the compound is in the form of particles wherein at least 90% of the particles are greater than 0.1 microns and less than 100 microns.
13. The crystalline form of claim 9 , wherein said compound comprises less than 0.5% impurities.